-+ 0.00%
-+ 0.00%
-+ 0.00%

NEUROCRINE BIOSCIENCES INC: PHASE 3 KINECT DCP STUDY EVALUATING EFFICACY, SAFETY OF VALBENAZINE DID NOT MEET PRIMARY OR KEY SECONDARY ENDPOINTS

Reuters·12/22/2025 21:05:00

Please log in to view news